Cargando…
Retracted: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
Ivermectin is an antiparasitic drug being investigated for repurposing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Ivermectin showed in vitro activity against SARS-COV-2, but only at high concentrations. This meta-analysis investigated ivermectin in 23 randomized clinical t...
Autores principales: | Hill, Andrew, Garratt, Anna, Levi, Jacob, Falconer, Jonathan, Ellis, Leah, McCann, Kaitlyn, Pilkington, Victoria, Qavi, Ambar, Wang, Junzheng, Wentzel, Hannah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420640/ https://www.ncbi.nlm.nih.gov/pubmed/34796244 http://dx.doi.org/10.1093/ofid/ofab358 |
Ejemplares similares
-
Retraction to: Meta-analysis of Randomized Trials of Ivermectin to Treat
SARS-CoV-2 Infection
por: Hill, Andrew, et al.
Publicado: (2022) -
RETRACTED: Expression of Concern: “Meta-analysis of Randomized Trials of
Ivermectin to Treat SARS-CoV-2 Infection”
por: Hill, Andrew, et al.
Publicado: (2021) -
529. Systematic Review and Meta-Analysis of Ivermectin Safety Profile in COVID-19 Trials
por: Wentzel, Hannah, et al.
Publicado: (2021) -
Ivermectin for the prevention of COVID-19: addressing potential bias and medical fraud
por: Hill, Andrew, et al.
Publicado: (2022) -
407. Minimum Manufacturing Costs, National Prices and Estimated Global Availability of New Repurposed Therapies for COVID-19
por: Wang, Junzheng, et al.
Publicado: (2021)